NC
SNOA icon

NewSquare Capital’s Sonoma Pharmaceuticals SNOA Stock Holding History

NewSquare Capital’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1
Closed -$11 – 863
2023
Q2 		$11 Hold
1
– – ﹤0.01% 846
2023
Q1 		$10 Hold
1
– – ﹤0.01% 878
2022
Q4 		$11 Buy
+1
New +$36 ﹤0.01% 819

Other funds holding SNOA

TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

NewSquare Capital's SNOA Position: Q3 2023 in Review

NewSquare Capital sold out of Sonoma Pharmaceuticals (SNOA) in Q3 2023, closing a stake of 1 share — an estimated $11 sold.

NewSquare Capital first reported a position in SNOA in Q4 2022 and held it in 3 quarters. The position peaked at $11 in Q2 2023. 12 funds tracked by Wall St. Rank hold SNOA as of Q3 2023.

  • NewSquare Capital reported no remaining Sonoma Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • NewSquare Capital sold 1 Sonoma Pharmaceuticals share in Q3 2023, an estimated $11.
  • NewSquare Capital first reported a position in Sonoma Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • NewSquare Capital's Sonoma Pharmaceuticals position peaked at $11 in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q3 2023.

Based on NewSquare Capital's 13F filing for Q3 2023, filed 3 Nov 2023.